Detailed Information

Cited 34 time in webofscience Cited 22 time in scopus
Metadata Downloads

The role of primary tumor resection in colorectal cancer patients with asymptomatic, synchronous, unresectable metastasis: A multicenter randomized controlled trial

Authors
Park, E.J.Baek, J.-H.Choi, G.-S.Park, W.C.Yu, C.S.Kang, S.-B.Min, B.S.Kim, J.H.Kim, H.R.Lee, B.H.Oh, J.H.Jeong, S.-Y.Jung, M.Ahn, J.B.Baik, S.H.
Issue Date
Aug-2020
Publisher
MDPI
Keywords
Chemotherapy; Colorectal neoplasm; Neoplasm metastasis; Non-curative resection; Overall survival; Primary tumor resection; Synchronous unresectable metastasis
Citation
Cancers, v.12, no.8
Journal Title
Cancers
Volume
12
Number
8
URI
https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/78758
DOI
10.3390/cancers12082306
ISSN
2072-6694
Abstract
We aimed to assess the survival benefits of primary tumor resection (PTR) followed by chemotherapy in patients with asymptomatic stage IV colorectal cancer with asymptomatic, synchronous, unresectable metastases compared to those of upfront chemotherapy alone. This was an open-label, prospective, randomized controlled trial (ClnicalTrials.gov Identifier: NCT01978249). From May 2013 to April 2016, 48 patients (PTR, n = 26; upfront chemotherapy, n = 22) diagnosed with asymptomatic colorectal cancer with unresectable metastases in 12 tertiary hospitals were randomized (1:1). The primary endpoint was two-year overall survival. The secondary endpoints were primary tumor-related complications, PTR-related complications, and rate of conversion to resectable status. The two-year cancer-specific survival was significantly higher in the PTR group than in the upfront chemotherapy group (72.3% vs. 47.1%; p = 0.049). However, the two-year overall survival rate was not significantly different between the PTR and upfront chemotherapy groups (69.5% vs. 44.8%, p = 0.058). The primary tumor-related complication rate was 22.7%. The PTR-related complication rate was 19.2%, with a major complication rate of 3.8%. The rates of conversion to resectable status were 15.3% and 18.2% in the PTR and upfront chemotherapy groups. While PTR followed by chemotherapyresulted in better two-year cancer-specific survival than upfront chemotherapy, the improvement in the two-year overall survival was not significant. © 2020 by the authors. Licensee MDPI, Basel, Switzerland.
Files in This Item
There are no files associated with this item.
Appears in
Collections
의과대학 > 의학과 > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Related Researcher

Researcher Baek, Jeong-Heum photo

Baek, Jeong-Heum
College of Medicine (Department of Medicine)
Read more

Altmetrics

Total Views & Downloads

BROWSE